Dorand R Dixon, Nthale Joseph, Myers Jay T, Barkauskas Deborah S, Avril Stefanie, Chirieleison Steven M, Pareek Tej K, Abbott Derek W, Stearns Duncan S, Letterio John J, Huang Alex Y, Petrosiute Agne
Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
Division of Pediatric Hematology-Oncology, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Angie Fowler Adolescent and Young Adult Cancer Institute and University Hospitals Rainbow Babies and Children's Hospital, Cleveland, OH 44106, USA.
Science. 2016 Jul 22;353(6297):399-403. doi: 10.1126/science.aae0477. Epub 2016 Jul 21.
Cancers often evade immune surveillance by adopting peripheral tissue- tolerance mechanisms, such as the expression of programmed cell death ligand 1 (PD-L1), the inhibition of which results in potent antitumor immunity. Here, we show that cyclin-dependent kinase 5 (Cdk5), a serine-threonine kinase that is highly active in postmitotic neurons and in many cancers, allows medulloblastoma (MB) to evade immune elimination. Interferon-γ (IFN-γ)-induced PD-L1 up-regulation on MB requires Cdk5, and disruption of Cdk5 expression in a mouse model of MB results in potent CD4(+) T cell-mediated tumor rejection. Loss of Cdk5 results in persistent expression of the PD-L1 transcriptional repressors, the interferon regulatory factors IRF2 and IRF2BP2, which likely leads to reduced PD-L1 expression on tumors. Our finding highlights a central role for Cdk5 in immune checkpoint regulation by tumor cells.
癌症常常通过采用外周组织耐受机制来逃避免疫监视,比如程序性细胞死亡配体1(PD-L1)的表达,抑制该配体可产生强大的抗肿瘤免疫力。在此,我们表明,细胞周期蛋白依赖性激酶5(Cdk5),一种在有丝分裂后神经元及多种癌症中高度活跃的丝氨酸-苏氨酸激酶,使得髓母细胞瘤(MB)能够逃避免疫清除。γ干扰素(IFN-γ)诱导的MB上PD-L1上调需要Cdk5,并且在MB小鼠模型中破坏Cdk5表达会导致强大的CD4(+) T细胞介导的肿瘤排斥反应。Cdk5缺失导致PD-L1转录抑制因子——干扰素调节因子IRF2和IRF2BP2的持续表达,这可能导致肿瘤上PD-L1表达降低。我们的发现凸显了Cdk5在肿瘤细胞免疫检查点调节中的核心作用。
EMBO J. 2018-11-5
Cancer Res. 2013-12-13
Naunyn Schmiedebergs Arch Pharmacol. 2025-4-11
Cell Death Discov. 2025-4-1
Biosaf Health. 2023-4-13
Front Immunol. 2025-1-22
Signal Transduct Target Ther. 2025-1-13
Signal Transduct Target Ther. 2024-12-30
Science. 2016-4-8
Cancer Immunol Res. 2014-2
PLoS One. 2014-2-14
Biochem Pharmacol. 2012-7-4
Nat Rev Cancer. 2012-3-22